T1	Intervention 41 86	ebrotidine in the treatment of duodenal ulcer
T2	Intervention 153 308	Ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene)amino]-4 -thiazoly]methyl]thio]ethyl]amino]methylene]-4-bromo-benzenesulfon amide, CAS 100981-43-9, FI-3542)
T3	Intervention 494 609	ebrotidine, administered in four dosages as a single evening dose versus placebo in the treatment of duodenal ulcer
T4	Intervention 742 959	The patients were assigned to 5 groups: placebo, 200 mg, 400 mg, 600 mg and 800 mg of ebrotidine once daily. Controls were performed at baseline and every two weeks at four follow-up visits unless ulcer healed before.
T5	Intervention 1203 1213	ebrotidine
T6	Intervention 1759 1790	ebrotidine (400, 600 and 800 mg
T7	Intervention 2226 2236	ebrotidine
